University of Chicago
This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). When non-Hodgkin lymphoma returns (relapses) or stops responding to treatment (refractory), standard options like chemotherapy or common targeted drugs can become ineffective. This study evaluates a treatment approach called CAR T-cell therapy. CAR T-cell therapy uses a participant's own immune cells (T cells) to hunt down and fight cancer. Participants in this study will first have their T cells collected through a process called leukapheresis, where…
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2 * At least 1 measurable lesion according to the Lugano Response Criteria for Malignant Lymphoma70 * Measurable disease defined as ≥ 1 measurable nodal lesion (long axis \> 1.5 cm and short axis \> 1.0 cm) or ≥ 1 measurable extranodal lesion (long axis \> 1.0 cm) on computed tomography (CT) or magnetic resonance imaging (MRI) * Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy * Total bilirubin ≤ 2.0 mg…
* Dose Level -1 (Lowered Dose): 5 x 10\^5 cells/kg (500,000 cells/kg) given as a single intravenous (IV) infusion. Dose level -1 is a lowered dose that will be given if participants have serious side effects to the starting dose (dose level 1). * Dose Level 1 (Starting Dose): 1 x 10\^6 cells/kg (1,000,000 cells/kg) given as a single intravenous (IV) infusion * Dose Level 2: 2 x 10\^6 cells/kg (2,000,000 cells/kg) given as a single intravenous (IV) infusion * Dose Level 3: 3 x 10\^6 cells/kg (3,000,000 cells/kg) given as a single intravenous (IV) infusion
Fludarabine: 30 mg will be given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The fludarabine dose remains the same (30 mg) across all dose levels (Level -1 through Level 3).
Cyclophosphamide: 300 mg given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The cyclophosphamide dose remains the same (300 mg) across all dose levels (Level -1 through Level 3).
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.